Updated

Updated · Oncodaily · Jun 11

Daraxonrasib Shows Promise in 1st Targeted Advance for Metastatic Pancreatic Cancer

Updated

Updated · Oncodaily · Jun 11

Daraxonrasib Shows Promise in 1st Targeted Advance for Metastatic Pancreatic Cancer

1 articles · Updated · Oncodaily · Jun 11

CancerWorld highlighted emerging data on daraxonrasib, a RAS(ON) inhibitor that Dr. Shiraj Sen said could mark a turning point in metastatic pancreatic cancer.
The interview frames the drug as the first targeted therapy to show such promise in a disease long dominated by chemotherapy.
RAS-targeted treatment is being presented as a potential breakthrough for researchers seeking new options in one of cancer care’s hardest-to-treat settings.

Sources

A new drug doubles pancreatic cancer survival. What is the real-world cost for patients who need this breakthrough therapy?

Researchers finally cracked an 'undruggable' cancer target. Which other deadly diseases could this new approach conquer next?

Beyond survival stats, how does this 'paradigm shift' drug truly change daily quality of life for pancreatic cancer patients?

1 total